Humanigen (OTCQB:HGEN +4.2%) will host an investor call and webcast to discuss the National Institute of Health’s selection of lenzilumab, its proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody drug candidate, as an agent to be evaluated in the NIAID-sponsored Big Effect Trial in hospitalized patients with COVID-19.
Call and webcast scheduled for today at 4:30 pm ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.